Tag Archive: vaccine development

  1. EAVI2020 continues the fight | World AIDS Day 2021

    Leave a Comment

    For World AIDS Day 2021, the EAVI2020 clinicians and researchers are shedding a light on the EAVI2020 clinical trials that aim to help accelerate the search for an effective HIV vaccine. Every year on 1st December since 1988, World AIDS Day is an international day dedicated to raising awareness of the AIDS pandemic caused by the spread of the HIV virus. According to WHO, since the beginning of the pandemic, 36.3 million people have lost their lives and it was estimated that there were 37.7 million people living with HIV at the end of 2020, over two thirds of whom (25.4 million) are in the WHO African Region.

    It is a day to remember those who have perished due to AIDS and that international research projects such as EAVI2020, are continuing the fight to find an effective vaccine for the HIV virus that has so far evaded eradication for the past 30+ years. Learn more about EAVI2020’s clinical trials and what the dedicated consortium of researchers and clinicians aim to achieve.

    Click on each image to find out about EAVI2020’s clinical trials.

    info card on clinical trial HIV-CORE 0051

    HIV-CORE 0051

    info card on clinical trial HIV-CORE 0052

    HIV-CORE 0052

    info card on clinical trial EAVI2020 - 3SM

    EAVI2020-3SM

    info card on clinical trial EAVI2020_01

    EAVI2020-01

    info card on clinical trial BCN03

    BCN03

    Follow World AIDS Day campaigns on Twitter with #Rocktheribbon

    To donate and show your support, go to the National AIDS Trust website

  2. World AIDS DAY Part 4: EAVI2020’s research to a better future | Trial HIV-CORE 0051

    Leave a Comment

    Hi! I am Trial HIV-CORE 0051. I am a phase 1/2a open-label trial to assess the safety and immunogenicity of candidate T-cell vaccines ChAdOx1.HTI and MVA.HTI given sequentially to healthy HIV-1/2 negative adult volunteers at the Jenner Institute, University of Oxford. Our trial aims to establish the initial safety and immunogenicity of the candidate on the path towards a preventive use of this strategy and is complemented by a series of HIV cure trials in early-treated PLWH.

    The HIV-CORE 0051 team including Dr Paola Cicconi (Principal Investigator) Prof Tomáš Hanke (Non-Clinical Principal Investigator), Dr Nicola Borthwick and Dr Edmund Wee (Immunology Laboratory Leads) and trial managers Dr Alison Crook and Ms Molly Glaze along with the many other team members that make up the HIV-CORE 0051 Trial team, in close collaboration with AELIX.

    The trial evaluates a candidate T-cell vaccine, which are being developed by a biotech company, AELIX Therapeutics. The regimen utilizes a prime with engineered replication-deficient simian (chimpanzee) adenovirus vector ChAdOx1 followed by a heterologous boost with a replication-deficient poxvirus vector called MVA. Both vectors deliver protein HTI (HIVACAT T-cell Immunogen) designed to generate protective HIV-1-specific T-cell targeting vulnerable sites of HIV-1. The HTI design was informed by human data, whereby the HTI-specific T cells were associated with better viral control in more than 1,000 people living with HIV-1 (PLWH) within a broad HLA class I and class II allele coverage. The immunogen was designed by the team led by Professor Christian Brander and Dr Beatriz Mothe at the Institut de Recerca de la Sida – IrsiCaixa in Barcelona.

    For the last decade, the HIV vaccine development has been almost entirely preoccupied with antibody-based protection, while the T-cell vaccines have been sadly ignored. It is only recently that highly rational T-cell strategies are being resurrected mainly in the context of HIV cure, where effective killer T cells will likely be key for drug-free HIV remission, perhaps even eradication. Current prevention focuses on behavioural and biomedical interventions and provision of antiretroviral drugs, however, an effective HIV-1 vaccine will help many people beyond the reach of today’s treatment and prevention options. Our trial which is aiming to understand the mechanisms and paths towards induction of protective T cells is therefore highly topical.

    Find out more about the other EAVI2020 trials taking place.

    info card on clinical trial HIV-CORE 0052

    HIV-CORE 0052

    info card on clinical trial EAVI2020 - 3SM

    EAVI2020-3SM

    info card on clinical trial EAVI2020_01

    EAVI2020-01

    info card on clinical trial BCN03

    BCN03

    Follow World AIDS Day campaigns on Twitter with #Rocktheribbon

    To donate and show your support, go to the National AIDS Trust website

    For World AIDS Day 2021, the EAVI2020 clinicians and researchers are shedding a light on the EAVI2020 clinical trials that aim to help accelerate the search for an effective HIV vaccine. Every year on 1st December since 1988, World AIDS Day is an international day dedicated to raising awareness of the AIDS pandemic caused by the spread of the HIV virus. According to WHO, since the beginning of the pandemic, 36.3 million people have lost their lives and it was estimated that there were 37.7 million people living with HIV at the end of 2020, over two-thirds of whom (25.4 million) are in the WHO African Region.

    It is a day to remember those who have perished due to AIDS and that international research projects such as EAVI2020, are continuing the fight to find an effective vaccine for the HIV virus that has so far evaded eradication for the past 30+ years. Learn more about EAVI2020’s clinical trials and what the dedicated consortium of researchers and clinicians aim to achieve.

  3. World AIDS DAY Part 5: EAVI2020’s research to a better future | Trial BCN03

    Leave a Comment

    Hi, I am EAVI2020 trial BCN03. Our trial takes place at IRSICAIXA with Christian Brander (Principal Investigator, IRSICAIXA) Beatriz Mothe (Principal Investigator, IRSICAIXA), working in collaboration with Rogier Sanders (Principal Investigator, AMC) and Dietmar Katinger (Principal Investigator, POLYMUN). Our trial focuses on a combined T- and B-cell, therapeutic HIV vaccine combining the HTI T cell vaccines with SOSIP envelope immunogens.

    Our trial is primarily focusing on the safety of the intervention and whether the intervention can induce sustained virus control once antiretroviral therapy (ART) is stopped. What sets our trial apart is that this is the first therapeutic vaccine trial that combines potent T and B cell immunogens in a combination regimen. We are hoping that this trial will test whether the addition of a B cell immunogen component to a T cell vaccine regimen can improve post-vaccination virus control compared to a single component regimen.

    Find out more about the other EAVI2020 trials taking place

    info card on clinical trial HIV-CORE 0051

    HIV-CORE 0051

    info card on clinical trial HIV-CORE 0052

    HIV-CORE 0052

    info card on clinical trial EAVI2020 - 3SM

    EAVI2020-3SM

    info card on clinical trial EAVI2020_01

    EAVI2020-01

    Follow World AIDS Day campaigns on Twitter with #Rocktheribbon

    To donate and show your support, go to the National AIDS Trust website

    For World AIDS Day 2021, the EAVI2020 clinicians and researchers are shedding a light on the EAVI2020 clinical trials that aim to help accelerate the search for an effective HIV vaccine. Every year on 1st December since 1988, World AIDS Day is an international day dedicated to raising awareness of the AIDS pandemic caused by the spread of the HIV virus. According to WHO, since the beginning of the pandemic, 36.3 million people have lost their lives and it was estimated that there were 37.7 million people living with HIV at the end of 2020, over two-thirds of whom (25.4 million) are in the WHO African Region.

    It is a day to remember those who have perished due to AIDS and that international research projects such as EAVI2020, are continuing the fight to find an effective vaccine for the HIV virus that has so far evaded eradication for the past 30+ years. Learn more about EAVI2020’s clinical trials and what the dedicated consortium of researchers and clinicians aim to achieve.

  4. World AIDS DAY Part 2: EAVI2020’s research to a better future | Trial HIV-CORE 0052

    Leave a Comment

    Hi! I am Trial HIV-CORE 0052; a phase I open-label trial aiming to establish and assess the safety and immunogenicity of candidate T-cell vaccines ChAdOx1.tHIVconsv1 and MVA.tHIVconsv3+MVA.tHIVconsv4 given in combination to healthy volunteers at low risk for HIV-1 infection at The Jenner Institute, University of Oxford London (Trial Sponsor) which will be followed by further studies towards both prevention of HIV infection and an HIV cure.

    The HIV-CORE 0052 team including Dr Paola Cicconi (Principal Investigator) Prof Tomáš Hanke (Non Clinical Principal Investigator), Dr Nicola Borthwick and Dr Edmund Wee (Immunology Laboratory Leads) and trial managers Dr Alison Crook and Ms Molly Glaze are aiming to test a candidate T-cell vaccine strategy against HIV-1. The tested regimen consists of a prime with engineered replication-deficient simian (chimpanzee) adenovirus vector ChAdOx1 followed by a heterologous boost with two replication-deficient poxviruses called MVA. These vectors deliver three unique mosaic algorithm-computed immunogens derived from the six most functionally conserved regions of the HIV proteome, collectively called HIVconsvX. Two regions are from the Gag including the whole capsid protein p24 and four are from the Pol proteins. These regions are common to most global HIV-1 variants and are hard to change and escape. These vaccines are so-called subunit genetic vaccines, are designated ChAdOx1.tHIVconsv1, MVA.tHIVconsv3 and MVA.tHIVconsv4 and aim to induce protective killer T-cell responses targeting HIV-1 ‘where it hurts’. If effective, they could work across all major HIV-1 clades and be deployed in all geographical regions.

    Throughout the challenging years of HIV vaccine development, when for the last decade most of the field has almost entirely focused on B-cell biology and antibody-based protection, Professor Hanke remained standing as one of a very few T-cell vaccinologists believing in vaccine-inducible protective cellular immunity, improving, and testing his highly rational T-cell strategy, which is now very much at the forefront of the current efforts.

    An HIV vaccine is urgently needed, however, simple vaccine solutions for this most difficult of viruses have remained extremely elusive. Development of an effective vaccine has been a slow and difficult process over four decades, but remarkable progress has been made in recent years. The experience with COVID-19 vaccines underscores how technologies under development for decades, such as RNA vaccines from 2001 and adenoviral vectors since 1991, can suddenly emerge as a leading and highly effective approach by building on decades of effort. Prof Hanke thinks it is likely that T cell-inducing vaccines for HIV-1 will reach this tipping point in the next 5 years and emerge as an additional tool to help control the HIV pandemic.

    Find out more about the other EAVI2020 trials taking place

    info card on clinical trial HIV-CORE 0051

    HIV-CORE 0051

    info card on clinical trial EAVI2020 - 3SM

    EAVI2020-3SM

    info card on clinical trial EAVI2020_01

    EAVI2020-01

    info card on clinical trial BCN03

    BCN03

    Follow World AIDS Day campaigns on Twitter with #Rocktheribbon

    To donate and show your support, go to the National AIDS Trust website

    For World AIDS Day 2021, the EAVI2020 clinicians and researchers are shedding a light on the EAVI2020 clinical trials that aim to help accelerate the search for an effective HIV vaccine. Every year on 1st December since 1988, World AIDS Day is an international day dedicated to raising awareness of the AIDS pandemic caused by the spread of the HIV virus. According to WHO, since the beginning of the pandemic, 36.3 million people have lost their lives and it was estimated that there were 37.7 million people living with HIV at the end of 2020, over two-thirds of whom (25.4 million) are in the WHO African Region.

    It is a day to remember those who have perished due to AIDS and that international research projects such as EAVI2020, are continuing the fight to find an effective vaccine for the HIV virus that has so far evaded eradication for the past 30+ years. Learn more about EAVI2020’s clinical trials and what the dedicated consortium of researchers and clinicians aim to achieve.

  5. World AIDS DAY Part 3: EAVI2020’s research to a better future | Trial EAVI2020_01

    Leave a Comment

    Hi! I am trial EAVI2020_01. Here at Imperial College London, both scientists and clinicians are leading my study which is modelling the interaction between rationally designed synthetic model viral protein immunogens (EAVI2020_01). We are studying immune responses to several different proteins that are modelled on HIV. The immunogens have a protein-adjuvant design and are given as an injection into the arm.

    Despite global efforts, HIV has proven one of the most difficult infections against which to develop a vaccine. We use sophisticated proteins that have been precisely developed to overcome these natural barriers. If the responses are promising, then we will have an early blueprint for making an HIV vaccine. Working on this trial are Professor Robin Shattock (Imperial College London, Scientific Lead), Dr Katrina Pollock (Imperial College London, Chief Investigator), and Dr Hannah Cheeseman (Imperial College London, Laboratory Lead).

    Vaccines are typically developed by focussing on the infection and not the immune response. The effectiveness of these vaccines is dependent on how most of us would usually respond to the infection if we were to come into contact with it. This strategy for making vaccines is restricting. For example, almost everyone who gets exposed to HIV will develop life threatening diseases without treatment.  The usual immune response is not protective.  The EAVI2020_01 study takes a different approach. Proteins that mimic the hidden parts of HIV are given several times to shepherd the body’s response precisely to make antibodies. The aim is that these antibodies will be broadly protective against all strains of HIV.

    The goal of HIV vaccine research is to make vaccines that induce broadly protective antibodies. This study will tell us how close we are to being able to do that. A successful outcome would pioneer the design of new vaccines for HIV and other highly challenging infectious diseases.

    Find out more about the other EAVI2020 trials taking place.

    info card on clinical trial HIV-CORE 0051

    HIV-CORE 0051

    info card on clinical trial HIV-CORE 0052

    HIV-CORE 0052

    info card on clinical trial EAVI2020 - 3SM

    EAVI2020-3SM

    info card on clinical trial BCN03

    BCN03

    Follow World AIDS Day campaigns on Twitter with #Rocktheribbon

    To donate and show your support, go to the National AIDS Trust website

    For World AIDS Day 2021, the EAVI2020 clinicians and researchers are shedding a light on the EAVI2020 clinical trials that aim to help accelerate the search for an effective HIV vaccine. Every year on 1st December since 1988, World AIDS Day is an international day dedicated to raising awareness of the AIDS pandemic caused by the spread of the HIV virus. According to WHO, since the beginning of the pandemic, 36.3 million people have lost their lives and it was estimated that there were 37.7 million people living with HIV at the end of 2020, over two-thirds of whom (25.4 million) are in the WHO African Region.

    It is a day to remember those who have perished due to AIDS and that international research projects such as EAVI2020, are continuing the fight to find an effective vaccine for the HIV virus that has so far evaded eradication for the past 30+ years. Learn more about EAVI2020’s clinical trials and what the dedicated consortium of researchers and clinicians aim to achieve.

  6. EAVI2020 quarterly newsletter | April 2021

    Leave a Comment

    Download the April 2021 newsletter (.pdf)

     

    In this issue:

    • EAVI2020 receives extension and clinical trials resume
    • EAVI2020 consortium at HIVR4P
    • Students in Focus: Narcís Saubi, Vall d’Hebron Research Institute (VHIR)
    • Publications with EAVI2020
    • EAVI2020 out and about: International Women’s Day
    • HIV/AIDS news: COVID-19 disruptions to HIV prevention could increase new infections amongst men
    • Other news: EAVI2020 lead investigator, Prof Robin Shattock profiled in The Lancet

     

    Foreword from Robin 

    Following a challenging year in the face of the COVID-19 pandemic the consortium is excited to be progressing again at full speed.

    We were delighted to receive a no cost extension from the EU that will allow us to complete our full programme of research and make up for delays caused by multiple lockdowns across the EU. We continue to invest in the training and mentorship of gifted young researchers to ensure a rich talent pool for the future, some of whom are highlighted in this newsletter. In our final year we are conducting seven clinical trials to evaluate ten new vaccine candidates, demonstrating an unprecedented level of translation from discovery to clinical evaluation. Our clinical trials are underpinned by an integrated approach designed to maximise our understanding of human immunity to vaccination and the pathways for driving B and T cell breadth to combat the extraordinary diversity of circulating HIV strains. These studies will be the culmination of our discovery program, will significantly expand scientific understanding and provide a pipeline of products with potential for moving into later stage product development. The entire EAVI2020 team are galvanised around maximising the potential of our discovery program and building a sustainable legacy for HIV vaccine research in the EU.

    Professor Robin Shattock
    EAVI2020 coordinator and on behalf of the EAVI2020 consortium

    Read the rest of the newsletter here

  7. EAVI2020’s final newsletter of 2020 – Looking back and looking forward

    Leave a Comment

    EAVI2020 Newsletter December 2020 (.pdf opens in a new window)

    2020 has been a bumpy ride (to say the least) for everyone, including EAVI2020. Clinical trials had to come to a standstill due to lockdown restrictions and as a result, EAVI2020 received a no-cost extension from its funding body, The European Commission to make up lost time. Yet, the EAVI2020 consortium still have worked tirelessly, if not more so this year, to continue to develop and evaluate EAVI2020 vaccine candidates. This issue exemplifies the continued work of the EAVI2020 consortium and while it only covers the last three months, it is a testimony that even during a global pandemic, the EAVI2020 consortium don’t stop. In this issue:

    • Forward from Prof Robin Shattock
    • COVID-19 and HIV vaccine R&D. Can one help the other?
    • Five years of EAVI2020 – Annual Meeting 2020
    • Prof Robin Shattock presents to European Parliament
    • The 10th PhD Training Course – The first online
    • Students in Focus: Alessandra Gallinaro & Dominik Dam
    • Publications with EAVI2020 research
    • EAVI2020 out and about (online)
    • Upcoming HIV/AIDS research events
  8. Professor Tomáš Hanke speaks to Scientia about innovative methods in vaccine design and development to combat HIV.

    Leave a Comment

    Prof Hanke, EAVI2020 PI at the University of Oxford spoke to Scientia which included his work on T cell response to second-generation conserved immunogen, HIVconsvX, and its predecessor, HIVconsv. Scientia is a popularised outreach journal that provides researchers with a platform to communicate their findings to others outside their speciality. Technical nomenclature is often transcribed into easier formats allowing further reach of the scientific outputs for maximising social impact, and engaging stakeholders.

    Read the full article at the Scientia website.

    Professor Tomáš Hanke – Use of Experimental Medicine for Rational Development of an Effective HIV Vaccine

    Aug 12, 2020 | BiologyHealth and Medicine

    Reference
    https://doi.org/10.33548/SCIENTIA538

    screenshot of Scientia article on website

  9. EAVI2020 Students in Focus: Nathifa Moyo (University of Oxford, UK)

    Leave a Comment

    It’s that time again to shine a light on EAVI2020’s students. So put up your feet, turn off the barrage of incoming COVID-19 news and let’s meet Nathifa Moyo.

    Written by Nathifa Moyo

    Profile photo of Nathifa Moyo

    Nathifa is a Senior Postdoctoral Immunologist at University of Oxford focussing on Studies on HIV-1 vaccine development

    My research within EAVI2020 is based at the Jenner Institute, University of Oxford, UK. There, as a Postdoctoral Immunologist in the laboratory of Professor Tomáš Hanke, my work is dedicated to performing in-depth analyses of vaccine-elicited responses in individuals and small animal models vaccinated with novel T cell-based immunogens. Multiple vectors for antigen delivery, such as simian (chimpanzee) adenovirus (ChAdOx1) and new technologies like mRNA, are being assessed to determine if these systems can enhance cellular immune responses.

    Initially, being a part of such a large consortium was challenging, as most projects aim to induce antibody-mediated immunity and my work aims to induce T-cell immunity. However, opportunities to participate in annual meetings offered knowledge exchange leading to a successful collaboration with consortium partners BioNTech and highlighted how all projects complement one another to ultimately achieve EAVI2020’s objectives.

    The early-stage career training programmes have been extremely rewarding and offered diverse topics with hands-on experience. These include GMP vaccine production at the Biotech company Polymun Scientific in Vienna, pre-clinical non-human primate studies at the CEA in Paris and assessing antibody-mediated responses at the Instituto de Salud Carlos III in Madrid. Collectively, they provided a greater understanding of how vaccines are progressed in an iterative process leading to the translation of the best strategies to clinics. To experience different research environments and learn from the experts in those labs have been tremendous and have inspired new research ideas. The generosity of staff, who gave their time to conduct these courses, has filled me with immense gratitude. To those students/postdocs considering similar programmes, please know that the benefits will be invaluable.

    It is hoped that my career will continue to advance within this field, incorporating host-pathogen interaction studies to improve vaccine design. The accomplishments of the consortium should be applauded and demonstrates that the collective efforts of the scientific community can have a greater impact.

    ——————————–

    Throughout the past four years, the students of EAVI2020 have worked tirelessly in The Continuing Education & Training in HIV vaccine development programme. This is a work package of the EAVI2020 project dedicated to the employment and training of young scientists in Europe. It comprises of scientific fellowships, student exchange, wet workshops, and a PhD Programme to maximise the training of the next generation of young scientists in the field of vaccine development. It is now time we shine a positive spotlight on the students to hear from them about their experience in the programme, lessons learned, and what they hope to achieve moving beyond EAVI2020s. ‘EAVI2020 Students in Focus’ will be a regular news feature so be sure to subscribe to the EAVI2020 newsletter to get the latest updates.  In this issue, we feature.

  10. In Pictures: EAVI2020 for World AIDS Day 2019

    Leave a Comment

    HIV continues to be a major global public health issue, having claimed more than 32 million lives so far (WHO). In the lead up to World AIDS Day 2019, EAVI2020 researchers reminded us of the necessity for an effective HIV vaccine.